Table Of Content

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR VOLUME 45, 1993 SUBJECT AND AUTHOR INDEX © Pergamon Press New York ¢ Oxford © Seoul ¢ Tokyo PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR Editor-in-Chief MATTHEW J. WAYNER Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662 Editorial Advisory Board ROBERT L. BALSTER, Virginia Commonwealth University, CONAN KORNETSKY, Boston University Medical Center, Richmond, VA Boston, MA BERNARD BEER, Medical Research Division of American J. DAVID LEANDER, Lilly Research Laboratories, Cyanamid, Pearl River, NY Indianapolis, IN ROBERT J. BLANCHARD, University of Hawaii, Honolulu, HI EMINY H. Y. LEE, Institute of Biomedical Sciences, Taipei, ALLAN C. COLLINS, University of Colorado at Boulder, Taiwan, Republic of China Boulder, CO ALLEN S. LEVINE, Veterans Administration Medical Center, DONALD V. COSCINA, Clark Institute of Psychiatry, Toronto, Minneapolis, MN Ontario, Canada WILLIAM J. McBRIDE, Indiana University School of Medicine, JACQUELINE N. CRAWLEY, Clinical Neuroscience Branch, Indianapolis, IN NIMH, Bethesda, MD DONALD E. MCMILLAN, University of Arkansas for Medical ADRIAN J. DUNN, Louisiana State University, Shreveport, LA Sciences, Little Rock, AR BURR EICHELMAN, Temple University, Philadelphia, PA H. MATTHIES, Medical Academy of Magdeburg, Magdeburg, JOHN L. FALK, Rutgers University, New Brunswick, NJ Germany SANDRA E. FILE, Guys Hospital Medical School, London, JACK H. MENDELSON, McLean Hospital, Belmont, MA England FATHY S. MESSIHA, University of North Dakota, WILLIAM J. FREED, National Institute of Mental Health, Grand Forks, ND Washington, DC LAURENCE R. MEYERSON, Marion Merrell Dow, Inc., RICHARD A. GLENNON, Virginia Commonwealth University, Kansas City, MO Richmond, VA LAWRENCE D. MIDDAUGH, Medical University of South A. J. GOUDIE, University of Liverpool, Liverpool, England Carolina, Charleston, SC F. G. GRAEFF, Universidad de Sao Paulo, Sao Paulo, Brazil ROBERT D. MYERS, East Carolina University School of Medicine, M. R. C. GREENWOOD, University of California at Davis, Greenville, NC Davis, CA KIM T. NG, LaTrobe University, Bundoora, Victoria, ROLAND R. GRIFFITHS, The Johns Hopkins University School of Australia Medicine, Baltimore, MD JAAK PANKSEPP, Bowling Green State University, J. HANO, Polish Academy of Sciences, Krakow, Poland Bowling Green, OH STEPHEN G. HOLTZMAN, Emory University School of Medicine, JOHN A. ROSECRANS, Medical College of Virginia, Atlanta, GA Richmond, VA AKIRA HORITA, University of Washington, Seattle, WA HERMAN H. SAMSON, Bowman Grey School of Medicine, WALTER A. HUNT, NIAAA, Rockville, MD Winston-Salem, NC JOSEPH P. HUSTON, University of Dusseldorf, Dusseldorf, PAUL R. SANBERG, University of South Florida, Tampa, FL Germany DAVID S. SEGAL, University of California School of Medicine, CHRIS E. JOHANSON, Addiction Research Center, La Jolla, CA Baltimore, MD PHIL J. SKOLNICK, National Institutes of Health, HAROLD KALANT, University of Toronto, Toronto, Ontario, Bethesda, MD Canada DEREK VAN DER KOOY, University of Toronto, Toronto, G. JEAN KANT, Walter Reed Army Institute of Research, Ontario, Canada Washington, DC JEANNE M. WEHNER, University of Colorado at Boulder, KATHLEEN M. KANTAK, Boston University, Boston, MA Boulder, CO ABBA J. KASTIN, Veterans Administration Medical Center, New J. C. WINTER, State University of New York School of Medicine, Orleans, LA Buffalo, NY GEORGE F. KOOB, Research Institute of Scripps Clinic, ALICE M. YOUNG, Wayne State University, Detroit, MI La Jolla, CA IAN S. ZAGON, M. S. Hershey Medical Center, Hershey, PA PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR Editorial Offices: Matthew J. Wayner Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West San Antonio, TX 78249-0662 Production Editor: Sara Beth Morrone Pergamon Press, Tarrytown, NY 10591-5153 Publishing, Subscription, and Advertising Offices: Pergamon Press Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, INTERNET “[email protected]” and Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 OBW, England Published Monthly ’ Annual institutional subscription rate (1993): £785 (US$1256) Sterling prices are definitive. US dollar prices are quoted for convenience only and are subject to exchange rate fluctuation. Prices include postage and insurance and are subject to change without notice. Pharmacology Biochemistry and Behavior, Vol. 45, pp . II-VI, 1993 009 1-3057/93 $6.00 + .00 Printed in the U.S.A. All rights reserved. Copyright © 1993 Pergamon Press Ltd. SUBJECT INDEX Aberrant drinking, 233 Antipsychotic(s), 9, 263 C57B1/6j mice, 65 Acetaldehyde, 215 Antipunishment, 263 Chickens, 117 Acetylcholine, 995 Anxiety, 1, 423, 429, 685, 803, 827, 931 Chlordiazepoxide, 263, 827 Acetylcholine release, 147 Anxiogenic, 967 Chloride-insensitive Mg-ATPase, 359 Acetylcholinesterase, 363, 713 Apomorphine, 655, 817 Chloride-sensitive Mg-ATPase, 359 Acquisition, 749 Arcurate nucleus, 837 Chlorpromazine, 263, 565 ACTH, 601 Atipamezole, 123 Cholecystokinin, 131 Activity, 553 Atropine, 209 Choline acetyltransferase, 19, 147, 283, 713 Acute ethanol, 95 Attention, 123 Cholinergic, 925 Adenosine, 913, 987 Atypical drinking, 741 Cholinergic antagonist, 639 Adenosine agonists, 951 Cholinesterase inhibitors, 309 Adenosine antagonists, 987 Baboon, 399 Chronic ethanol, 95 Adenosine A, receptors, 951 Barbital, 703 Chronic variable-stress regime, 665 Adenosine A, receptors, 951 Behavior, 179, 629, 777 Circadian rhythms, 27 Adrenocorticotropic hormone, 629 Behavioral reorganization, 655 Circling, 343 Adult oral catheter test, 243 Behavioral screen, 987 cis-flupenthixol, 343 Affective disorders, 247 Behavioral sensitization, 691 Cisplatin, 817 Aggression, 153, 549 Behavioral supersensitivity, 195 °C]~ influx, 423 Aging, 455 Benzodiazepine, 77 Clomipramine, 941 Alarm substance, 561 Benzodiazepine receptor, 827 Clonidine, 247, 607 Alcohol, 59 B-adrenergic receptors, 1 Clozapine, 51, 71, 263 Alcohol drinking, 233, 697, 741 Bevantolol HCl, 623 Cocaine, 179, 209, 229, 239, 269, 283, 399, Alcohol preference, 233 Bicuculline, 881 539, 549, 733, 749, 759, 905 Alcohol-preferring rats, 697 Bilirubin, 363 Cocaine withdrawal, 577 Alcoholism, 233, 741 Binding study, 65 Cognition, 897 Alkylxanthine, 913 Bipolar disorder, 247 Cola seeds, 791 a,-adrenoceptors, 123 Blood glucose, 369 Cold water swim, 161 a-difluoromethylornithine, 967 B lymphocytes, 665 Color and position discrimination, 107 a-methyl-p-tyrosine, 647 Body weight, 495 Conditioned avoidance responding, 951 a@,-receptor(s), 247, 269 Brain, 359, 419 Conditioned taste aversion, 147 Alprenolol, 269 Brain cortical polyamines, 967 Conditioning, 251, 733 Alzheimer’s disease, 925 Bulbectomy, 65 Conflict behavior, 429 Amfonelic acid, 71 Bulimia nervosa, 941 Consumatory behavior, 243 Amineptine, 897 Buspirone, 179 Contingent tolerance, 439 Aminorex, 229 Convulsion(s), 173, 561, 755, 823 Amnesia, 455 Caffeine, 791, 987 Copper sulfate, 817 Amperozide, 233, 741 Calcitonin, 507 Cortical B-adrenoceptor binding, 665 Amphetamine, 45, 71, 131, 629, 729 Calcium, 383 Corticosterone, 209, 419, 629 Amygdala kindling, 445 Calcium channel blockers, 703 Corticotropin-releasing factor, 419 Analgesia, 161, 251 Calcium channels, 439 CQ 32-084, 117 Anesthesia, 849 Cannabinoids, 291 CQP 201-403, 117 Angiotensin-converting enzyme inhibitors, Carbamates, 677 Cross-tolerance, 527 35, 811 Carbamazepine, 439 CXBK/ByJ, 251 Angiotensin II, 455 Carbohydrate, 185 Animal depression model, 201 Carrageenan, 507 DA agonist, 843 Animal model, 817 Catalepsy, 195 DA antagonist, 843 Animal models of depression, 27 Cathinone, 229 DAKLI, 315 Anisomycin, 225 Cat odor, 931 DAMGO, 315 Anorectics, 131 Cats, 849 d-amphetamine, 351, 589, 765 Anorexia, 45, 589 Caudate nucleus, 275, 913 D, and D, dopamine receptors, 291 Antianalgesia, 383 Caudate putamen, 343 DBA/2j mice, 65 Anticholinesterases, 677 Central 6,-adrenoceptor, 623 D-cycloserine, 983 Anticonvulsant(s), 247, 445, 913 Central injection, 979 D, dopamine receptors, 239 Anticonvulsant effect, 881 Cerebral activator, 445 Deermouse, 143, 785 Antidepressant drugs, 987 Cerebral arousal action, 335 Defensive withdrawal, 1 Antinociception, 383 Cerebral ischemia, 607, 945 Delayed-type hypersensitivity reaction, 665 Ill IV SUBJECT INDEX 6-agonist, 979 Fenugreek seed, 369 Immature rats, 19 6-opioid receptor, 697 FG 7142, 553, 827 Immobilization, 327 A’-tetrahydrocannabinol, 291 5-HIAA, 673 Immobilization stress, 623 Depression, 201 5-HT, 931 Immune response, 495 Deprivation, 359 5-HT jc, 221 Improved anticipation, 897 Desipramine, 201, 777 5-HT,, and 5-HT;\, receptors, 577 Indeloxazine HCl, 335, 445 Development, 283 5-HT, receptor agonists, 513 Inescapable shock, 553, 827 Dexfenfluramine, 495, 963 5-HT,, receptor(s), 65, 143, 269, 777, 785 Inflammatory nociception, 507 d-fenfluramine, 593 5-HT, receptors, 65, 233, 269, 777, 785 Inhibitory avoidance, 571 Diazepam, 445, 455, 755, 803, 881 5-HT; receptor antagonists, 755 Insular cortex, 147 Differential housing, 905 5-HT; receptors, 589 Interstimulus interval, 973 Diffusion, 857 5-HT receptor subtypes, 593 Intrathecal, 383 Diisopropylfluorophosphate, 309 5-hydroxytryptamine, 935 Intrathecal morphine, 871 Diltiazem, 703 Fixed-ratio responding, 565 Intrathecal serotonin, 871 Discrimination task, 519 Fluid exchange, 451 Ipsapirone, 513 Disulfoton, 309 Flumazenil, 597, 827 Isoproterenol, 1 Diurnal rhythms, 785 Flunarizine, 703 d-norfenfluramine, 185 Fluoxetine, 185, 941, 959 Jaw movements, 921 Dog, 897 Food, 131, 343 DOI, 269 Food deprivation, 601 Kainic acid, 55 Domperidone, 817 Food intake, 85, 487, 495 Ketamine, 889 DOPAC, 291, 327, 673 Food reward, 243 Kindling, 439, 619 Dopamine, 9, 45, 95, 173, 179, 291, 327, Forced swimming test, 201 507, 673, 685, 691, 725, 729, 837, 843, Forebrain cholinergic neurons, 283 Lactation, 393 897 Formalin, 501 Lateral hypothalamus, 455 Dopamine agonists, 685 4-methylaminorex, 229 Lateral parabrachial, 973 Dopamine antagonists, 243 Four-vessel occlusion model, 607 Lateral septum, 935 Dopamine D, and D, receptors, 797 Frontal cortex, 65, 327 Learned helplessness, 275, 553, 827 Dopamine D, receptors, 921 Learning, 59, 107, 571 Dopamine receptor interactions, 195 GABA, 77, 931 Learning and memory, 925 Dopamine receptors, 117, 655, 685 GABA,, 945 Learning behavior, 335 Dopamine receptors supersensitivity, 45 GABA, receptor complex, 299 Lesions of the nucleus basalis magnocellu- Dopamine release, 759 Gastric damage, 597 laris, 19 Dopaminergic drugs, 765 GDP binding, 487 Lethal effects, 465, 473 Dopaminergic systems, 233, 741 Generalized seizures, 857 Lever press, 399 Dose relationship, 857 Genetics, 251, 803 Lewis rat, 749 DPDPE, 315 Gepirone, 513 Limbic area, 65 D, receptor(s), 243, 765 Gerbil, 945 Linear locomotion, 315 D, receptor(s), 243, 765 Glucocorticoids, 991 Lithium chloride, 973 Drinking, 725 Glutamergic dysfunction, 519 Lobeline, 571 DRL 72-s schedule, 987 Glycine, 519 Locomotion, 629 Drug discrimination, 179, 221, 305, 865 Greek cross maze, 967 Locomotor activity, 315, 571, 691, 733, Drug state learning, 655 749, 843, 905, 913 DSP4, 429 Haloperidol, 71, 179, 263 Locomotor stereotypy, 71 Dynorphin, 383 Head-twitch response, 269 Locus coeruleus, 429 Heat production, 935 Long-term potentiation, 455 EEDQ, 797 Hemagglutinin titer, 665 Lordosis, 837 EEDQ inactivation, 921 Heroin self-administration, 963 Lorsartan, 455 EEG, 791 (H]flunitrazepam, 77 LS mice, 95 8-OH-DPAT, 513 High-fat diet, 487 Elevated plus-maze, 1, 423 Hippocampus, 89, 309, 455, 691, 935 Macaque, 677 Emesis, 817 Histamine agonists, 275 Mania, 247 Endogenous ligands, 827 Histamine antagonists, 275 Matching-to-sample, 925 Endogenous opioid peptides, 383 Hormones, 255 Maternal behavior, 673 Environment-dependent mice, 733 Hot-plate, 501 Maudsley rats, 429 Epilepsy, 321, 857 Hot-plate test, 153, 607 Maze, 639 Estrogen, 255 Human(s), 59, 549 MCPP, 221, 513 Ethanol, 225, 305, 327, 445, 455, 465, 473, HVA, 673 Meal patterns, 185 597, 755, 803, 983, 991 Hyperactivity, 393 Mecamylamine, 89, 533 Ethanol intake, 35 Hyperhydration, 451 Medroxyprogesterone acetate, 77 Ethanol preference, 741 Hyperlocomotion, 655 Memory, 455, 533, 571, 995 Etonidazole, 251 Hyperlocomotor activity, 755 Memory trace consolidation, 481 Excitotoxic lesion, 55 Hyperphagia, 941 Memory trace retrieval, 481 Exercise, 713 Hypertension, 623 Mesolimbic dopamine system, 673 Experimental depression, 275 Hypnotic effect, 881 Mesolimbic system, 233 Exploratory behavior, 1 Hypoalgesia, 501, 507 Mesolimbic system structures, 741 Extensor digitorum longus, 713 Hypothalamus, 65, 837 Metergoline, 185, 963 Hypothermia, 393, 935 Methamphetamine, 173, 691 Fat consumption, 255 Methaqualone, 351 Feeding, 131 ICV, 209 Methcathinone, 229 Feeding behaviour, 369 Idazoxan, 607 Methylphenidate, 71, 729 Fenfluramine, 131 Imipramine, 27, 201, 445, 561, 665 Mg**-ATPase, 363 SUBJECT INDEX MHPG-SO,, 419 Ontogeny of DA function, 243 Psychomotor stimulants, 987 Mianserin, 777 Open-field behavior, 201 Psychophysical procedure, 399 Mice, 251, 383, 905 Operant, 979 Psychostimulant, 791 Mice strains, 465 Operant behavior, 107 Putrescine, 967 Microdialysis, 327, 647, 673, 759 Operant responding, 343 PYY, 941 MIF-1, 615 Opiates, 255 Minaprine, 481 Opioid, 979 Quinpirole, 765 MK-212, 221, 593 Opioid antagonists, 409 MK-801, 321, 439 Opioid-nonopioid interactions, 161 Raclopride, 765 (+)MK-801, 983 Opioid peptide agonists, 315 Radial maze, 719 Monkey(s), 107, 131, 925 Opioid receptor antagonists, 697 Raphe, 995 Monoamines, 507 Optical isomer, 335 Rapid eye movement sleep, 359 Mood elevation, 455 Oral activity, 737 Rapid tolerance, 225, 983 Morphine, 161, 255, 393, 615 Oral administration, 905 Rat(s), 45, 51, 89, 123, 179, 201, 225, 239, Morphine drug discrimination, 963 Oral route, 749 283, 369, 473, 507, 533, 561, 577, 597, Morphine tolerance, 527 Organophosphates, 677 607, 639, 703, 719, 759, 765, 777, 791, Mortality, 55 Organophosphorus compounds, 309 817, 823, 827, 843, 857, 889, 963, 973, Motivation, 107 Organum vasculosum laminae terminalis, 995 Motor activity, 291, 729 811 Rat ALDH2 polymorphism, 215 Motor function, 765 Osborne-Mendel rats, 487 Reaction time, 351, 399 Motor impairment, 225 Ovariectomy, 423 Rearing, 315 Mouse, 173, 321, 393, 685 Receptor autoradiography, 945 Mouse lines, 527 Paeoniflorin, 719 Reference memory, 89, 639, 765 Mouse strains, 473 Pain, 507, 607 Reinforcement, 565, 697, 749 Muscarinic, 533 Pain mechanisms, 527 Release, 931 Muscarinic receptor(s), 309, 737 Palatability, 979 Respiration, 849 p-agonist, 979 PAPP, 865 Reward, 343, 979 p-opioid receptor, 697 Pargyline, 837 Rhythmic activity, 889 Mydriasis, 639 Passive avoidance conditioned response, 19 Ring-A-reduced metabolites, 77 Passive avoidance learning, 283 Ritanserin, 233 NaCl loads, 451 Pavlovian conditioning, 473 Ro 15-1788, 299, 827 Naked mole-rat, 153 p-chlorophenylalanine, 647 Ro 15-3505, 597 N-allylnormetazocine, 865 PD 116,600, 987 Ro 15-4513, 597 Naloxone, 209, 501, 527, 607, 615, 619, Pecking, 117 RU-24969, 221 941 Pentobarbital, 107, 383, 881 Runway task, 89 Naltrexone, 161, 553 Pentylenetetrazol, 823, 889 Negative symptoms, 9 Peony root, 719 Saccharin, 979 Neocortical focus, 889 Peptide YY, 941 Saline drinking, 513, 593 Neuroleptics, 51, 195, 263, 725 Peptides, 85 Saralasin, 455 Neurosteroid, 423 Perifornical hypothalamus, 45 Satiety, 85, 185 Neurotensin, 95 Pethidine, 153 SCH23390, 239, 539, 765, 843 Neurotensin receptors, 95 Pharmacokinetics, 791 Scopolamine, 533, 719, 925 Neurotoxicity, 647 Phencyclidine, 351 Sedation, 117 Neurotransmitter, 945 Phenoxybenzamine, 209 Sedative action, 991 Ng* ,K*-ATPase, 363 Phenytoin, 445 Seizures, 615, 619 Nicotine, 305, 375, 571, 803, 925 Phosphoinositide hydrolysis, 309 Selective 5-HT uptake inhibitors, 335 Nicotinic, 533 Physical dependence, 703 Selective NE uptake inhibitors, 335 Nicotinic receptor, 89 Physostigmine, 713 Self-administration, 131, 239, 539, 749 Nicotinic receptor agonists, 571 Pica, 817 Sensitization, 59, 577, 655, 729 Nigrostriatal neurons, 291 Picrotoxin, 619 Sensitization (2-day paradigm), 733 Nimodipine, 439 Pigeon(s), 351, 565 Sensorimotor impairment, 153 Nitric oxide, 321 Pilocarpine, 321, 737 Serotonergic system, 335 NMDA, 945 Pimozide, 209, 725 Serotonin, 9, 143, 263, 487, 507, 785, 865, NMDA antagonist, 983 Plasma cholesterol, 369 959, 995 NMDA receptors, 439 Plasma insulin, 369 Serotonin receptors, 233, 741 Nociception, 153, 255 Plasma triglycerids, 369 Serotonin-3 receptor, 759 Nonsmokers, 375 Platform, 359 S 5B/PI rats, 487 Noradrenaline, 419 P/NP rats, 305 Sheep, 601 Noradrenergic, 247, 429 Pontine reticular formation, 55 Short-term memory, 107 Noradrenergic system, 123, 335 Positive reinforcement, 243 o-receptors, 865 Norepinephrine, 507, 837 Postnatal recovery, 19 6-hydroxydopamine, 737 Novelty, 465, 473, 931 Postnatally developing rat brain, 363 SKF 38393, 765, 843 NPA, 797 Preening, 117 Smokers, 375 NSAIDs, 153 Pregnancy, 393 Sniffing, 797 Nuclei, 995 Prenatal drug effects, 959 Social behavior, 9 Nucleus accumbens, 673, 691, 759, 843 Proactive memory, 519 Social defeat, 161 Nucleus basalis magnocellularis, 147, 995 Procaine, 849 Social interaction, 827 Progestational agents, 77 Solcoseryl, 55 Obesity, 51 Progesterone, 77, 255 Soleus muscle, 713 Ondansetron, 539, 589, 593, 817 Progressive-ratio, 539 Spinal dynorphin A release, 409 One-way active avoidance, 481 Propranolol, 1, 209 Spinal morphine, 409 Ontogeny, 737, 797 Protective mechanisms, 857 Spinal opiate antinociception, 871 VI SUBJECT INDEX SS mice, 95 Taste aversion learning, 973 Tyr-MIF-1, 615 Status epilepticus, 55 Temporal regulation, 897 Tyrosine hydroxylase, 291 Stereotyped behaviors, 629 Temporal systems, 519 Stereotypic behavior, 291 TFMPP, 221, 513 Uptake, 931 Stereotypy, 315 Therapeutic treatment, 233, 741 Urine output, 451 Steroid actions on membranes, 991 Thermoregulation, 247, 935 Steroids, 77 Thigmotaxis, 315 Valproate, 247 Stress, 1, 161, 299, 327, 495, 629, 823, 827 Thioridazine, 71, 263 Valproic acid, 247 Stress-induced analgesia, 527 Thirst, 35, 513, 593, 725, 811 Vascular effects, 959 Stressor, 501 3a-hydroxy-5a-pregnan-20-one, 423 Ventral striatum, 673 Subfornical organ, 811 3,4-methylenedioxymethamphetamine, 647 Ventromedial nucleus, 837 Subjective responses, 375 Threshold, 399 Visual reinforcement, 131 Sucrose consumption, 255 Time perception, 107 Sulpiride, 45 T lymphocytes, 665 Water deprivation, 749 Supersensitization, 737 T-maze alternation, 533 Water intake, 451 Sweet taste, 243 T-maze discrimination, 533 Water maze, 571 Swim stress, 527 Tolerance, 59, 251, 375, 465, 473, 565, 577, White-dark maze, 967 Synaptoneurosomes, 423 619, 729 Working memory, 89, 639, 719, 765 Torpor, 143, 785 Tachypnea, 849 Tracking performance, 677 Yawning, 117 Tail-flick, 871 trans-flupenthixol, 343 Yohimbine, 269, 607 Tail-flick latency, 255 TRH, 601 Tail-flick test, 607 Tricyclic antidepressant, 897 Zacopride, 759 Tardive dyskinesia, 195 PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR VOLUME 45 1993 AUTHOR INDEX Abel, E. L., 561, 823 Cancela, L., 665 Ferchmin, P. A., 967 Hoganson, D. A., 507 Advokat, C., 871 Cao, W., 803 Ferguson, S. A., 107 Holmes, B. B., 409 Agnati, L. F., 607 Carey, R. J., 655 Fernandez-Ruiz, J., 147 Horikawa, Y., 173 Agiiero, A., 973 Carr, L. G., 215 Fernandez-Ruiz, J. J., 291 Horn, E., 857 Aksu, F., 409 Casamenti, F., 19 Ferrari, F., 117 Horvitz, J. C., 725 Aleksandrova, I. A., 65 Cebeira, M., 291 Ferrer, J., 439 Hulihan-Giblin, B. A., 143, Alemany, G., 275 Chase, T. N., 195 File, S. E., 931 785 Alexander, J. T., 185 Chau, A., 983 Fillmore, M. T., 59 Hyytia, P., 697 Allen, D. L., 837 Cheung, W. K., 185 Fisler, J. S., 487 Alleva, E., 283 Chleide, E., 897 Fitts, D. A., 35, 811 Iwashita, Y., 445 Aloe, L., 283 Chover, A. J., 239 Fleshner, M., 161 Altman, H. J., 429 Ciccocioppo, R., 513 Foo, H., 501 Jackson, H. C., 733 Ambrogi Lorenzini, C., 481 Collins, A. C., 803 Frasoldati, A., 607 Jackson, W. J., 925 Amit, Z., 465, 473 Commissaris, R. L., 429 Fregly, M. J., 451 Jacob, R. G., 375 Andrews, N., 931 Compton, A. D., 263 Friedhoff, A. J., 921 Jadot, G., 791 Anraku, T., 445 Conway, P. C., 9 Frye, C. A., 255 Jakala, P., 123 Anthony, P., 439 Cooper, S. J., 513, 589, 593 Fujimoto, J. M., 409 Janusz, C. A., 913 Araki, T., 945 Corbett, R., 9 Jarvis, M. F., 951 Armstrong, D. L., 455 Corwin, R. L., 131 Gallo, M., 973 Johannesen, T. S., 519 Arnedo, M., 973 Costentin, J., 685 Ganesan, R., 393 Jones, B. C., 905 Arneri¢, S. P., 571 Cranston, J., 549 Gibbs, J., 85 Joyner, C. M., 577 Cuevas, C. A., 255 Gilbert, D. B., 589 Babu, S. R., 713 Cui, Y., 935 Giuliani, D., 117 Kaczor, T., 351 Balansard, G., 791 Glennon, R. A., 229, 865 Kalant, H., 225, 983 Baldi, E., 481 Damianopoulos, E. N., 655 Goldberg, S. R., 251 Kanai, Y., 945 Baptista, T., 45, 51 D’Amico, C. M., 343 Goldman, D., 143, 785 Kanarek, R. B., 255 Barber, D. J., 593 Darmani, N. A., 269 Gordon, T. L., 305 Kanui, T. I., 153 Basso, A. M., 665 Davidson, E. S., 729 Gorman, A. L., 1 Kapitzoglou-Logothetis, V., Bell, S. M., 749 Decker, M. W., 571 Gosnell, B. A., 979 195 Beninger, R. J., 343 De Miguel, R., 291 Grauer, E., 639 Kapon, Y., 639 Bergvall, A. H., 673 Denny, J. B., 455 Greenwood, S. E., 589 Karim, K. H., 597 Berman, M., 549 Depiante-Depaoli, M., 665 Grimaldi, R., 607 Katkov, Y. A., 65 Berman, R. F., 823, 913 Depoortere, R. Y., 539 Grisel, J. E., 161 Kato, H., 945 Bermudez-Rattoni, F., 147 De Quijada, M., 51 Grobe, J. E., 375 Keith, A. B., 995 Bird, E., 209, Telegdy, G., 209 Deutsch, S. I., 299 Gulyani, S., 359 Kellogg, C. K., 423 Bitran, D., 423 Dewey, W. L., 383 Gurevich, E. V., 65 Kenigs, V., 615 Bitran, M., 225 Dhingra, P., 429 Kerman, L. L., 9 Bjork, A., 741 Dilsaver, S. C., 247 Haapalinna, A., 123 Khanna, J. M., 983 Blakely, E., 351 Dube, S. N., 713 Hagan, M. M., 941 Kigoshi, S., 623 Blick, D. W., 677 Dulchinos, V. F., 309 Han, H.-W., 51 King, G. R., 577 Bobek, S., 601 Dunn, A. J., 1 Hansen, S., 673 Knowlton, B., 55 Bobkova, N. V., 65 Dunn, R. W., 9 Harada, M., 335 Koga, C., 419 Bowers, D. A., 399 Dwyer, K. D., 201 Harper, R. K., 849 Kogure, K., 945 Brady, J. V., 399 Harper, R. M., 849 Koivisto, T., 215 Bray, G. A., 487 Ellinwood, Jr., E. H., 577 Harrington, G. M., 429 Koob, G. F., 239, 629 Brodkin, J., 647 Elmer, G. I., 251 Hartman, H., 9 Kostrzewa, R. M., 737 Brown, G. C., 677 Emmett-Oglesby, M. W., 539 Hasegawa, S., 817 Kroboth, P. D., 77 Bruhwyler, J., 897 Emoto, H., 419 Hauger, R. L., 629 Buccafusco, J. J., 925 Epstein, L. H., 375 Heffner, T. G., 987 Lane, J. D., 539 Bucherelli, C., 481 Eriksson, C. J. P., 215 Hegarty, A. A., 327 Lankford, M. F., 233, 741 Burkholder, T., 803 Erwin, V. G., 95, 905 Helsley, G. C., 9 Lee, T. F., 935 Bushnell, P. J., 765 Escobar, M. L., 147 Hernandez, L., 45, 51 Leibowitz, S. F., 185 Esseling, K., 857 Hernandez, M. L., 291 Levin, E. D., 765 Cade, J. R., 451 Eterovi¢c, V. A., 967 Herndon, J. L., 865 Li, A. A., 987 Cador, M., 629 Ettenberg, A., 725 Hienz, R. D., 399 Li, D. H., 539 Caggiula, A., 375 Higgins, G. A., 963 Li, T.-K., 215 Caine, S. B., 239 Fantino, M., 495 Hitri, A., 299 Licata, A., 549 Campbell, A. D., 95 Fave, A., 369 Hitzemann, R., 759 Lépez-Garcia, J. C., 147 Vill AUTHOR INDEX Lépez-Garcia, J. A., 275 Nakazawa, Y., 445 Richard, C. A., 849 Tanaka, M., 419 Lorang, M., 629 Nash, J. F., 647 Richards, J. B., 987 Tapia, R., 147 Luine, V. N., 837 Navarro, M., 291 Richardson, W. B., 725 Tassoni, G., 481 Lukacs, L. G., 299 Neely, D., 737 Riekkinen, P. J., 123 Taylor, S., 549 Lund, A., 777 Nesterova, I. V., 65 Riekkinen, Jr., P., 123 Telegdy, G., 209 Ni, H., 849 Rivera, E., 967 Teneud, L., 45, 51 Macenski, M. J., 749 Ni, J.-W., 719 Robledo, P., 239 Terry, Jr., A. V., 925 Maier, S. F., 161, 553, 827 Nicolau, M. C., 275 Rosengarten, H., 921 Thomas, J., 615, 619 Majchrzak, M. J., 571 Niezgoda, J., 601 Rossi, D. J., 951 Ticku, M. K., 755 Maldonado, R., 239 Noguchi, H., 703 Rowland, N. E., 451 Tilson, H. A., 309 Mallick, B. N., 359 Nores, W. L., 615, 619 Roy, E. J., 201 Tirassa, P., 283 Malyala, A., 647 Nose, I., 173 Toru, M., 691 Manteghetti, M., 369 Nutt, D. J., 733 Sadowski, B., 527 Towett, P. K., 153 Marek, G. J., 987 Nyiredi, S., 673 Sahgal, A., 995 Tsakiris, S., 363 Mare, P., 889 Sarnyai, Z., 209 Tsibulsky, V. L., 465, 473 Marin, C., 195 Ohno, M., 89 Sauvaire, Y., 369 Tsuda, A., 419 Marrama, P., 607 Ohta, H., 719 Scali, C., 19 Tyrka, A., 243 Martin, G. E., 951 Olson, G. A., 615 Schechter, M. D., 305 Mata, A., 51 Olson, R. D., 615 Schechtman, V. L., 849 Underberger, S. J., 487 Mathura, C. B., 251 Otmakhova, N. A., 65 Schenk, S., 729 Matsumoto, K., 719 Schuster, C. R., 131 Vaille, A., 791 Matsunaga, T., 817 Panissaud, C., 685 Schweitzer, J. W., 921 VeliSek, L., 889 Mazurkiewicz, M., 123 Panocka, I., 527 Sechman, A., 601 Verbanac, J. S., 429 McAuley, J. W., 77 Parashos, S. A., 195 Seiden, L. S., 987 Vogel, W. H., 327 McDougall, S. A., 797 Pariser, R., 619 Sellers, E. M., 963 Vogel-Sprott, M., 59 McNamara, C. G., 729 Park, C. H., 299 Shah, G., 983 Vondfitkova, R., 889 McNeish, C. S., 759 Park, Y. D., 143 Shaughnessy, R. A., 987 Meehan, S. M., 305 Patel, C. K., 979 Shibuya, H., 691 Wang, L. C. H., 935 Mehta, A. K., 755 Patton, J. H., 959 Shimizu, M., 719 Wang, Y., 963 Meisch, R. A., 749 Paule, M. G., 95 Shimizu-Sasamata, M., 335 Ward, T. R., 309 Melville, L. D., 85 Pelloni, F., 117 Shirouzu, M., 445 Watanabe, A., 691 Menaker, M., 27 Pepeu, G., 19 Short, K. R., 827 Watanabe, H., 719 Mercier, M., 897 Peppe, A., 195 Silbert, L. H., 553 Watanabe, S., 89 Mestlin, M., 797 Perkins, K. A., 375 Silverman, P. B., 749 Watkins, L. R., 161 Meyer, M. E., 315 Petit, P., 369 Simon, P., 685 Wayner, M. J., 455 Meyer, M. E., 315, 843 Pich, E. M., 607 Smith, F. L., 383 Weiss, G. F., 185 Miller, S. A., 677 Pivorun, E. B., 143, 785 Smith, G. P., 85, 243 Weiss, S. R. B., 439 Minkus, D., 247 Planas, B., 275 Smith, J. B., 565 Westbrook, R. F., 501 Mintz, M., 55 Poignant, J. C., 897 Somani, S. M., 713 Wiley, J. L., 263 Misawa, M., 703, 881 Polan-Curtain, J. L., 455 Sorvid, J., 123 Wilkins, L., 803 Mizoguchi, H., 703 Poling, A., 351 Souquet, A. M., 495 Winter, J. C., 221 Mijellem, N., 777 Ponsin, G., 369 Spear, D. J., 399 Woodmansee, W. W., 553 Molina, V., 665 Porter, J. H., 263 Spikkerud, E., 519 Woods, A. T., 9 Moran, P. M., 533 Post, R. M., 439 Stanford, M. S., 959 Wronska-Fortuna, D., 601 Morita, M., 817 Puerto, A., 973 Starr, B. S., 321 Morse, A. C., 905 Purdy, R. H., 423 Starr, M. S., 321 Yamada, S., 173 Moss, D. E., 941 Stiff, D. D., 77 Yamamoto, M., 335 Motegi, H., 881 Rabin, R. A., 221 Stiller, R. L., 375 Yamamoto, T., 89 Mueller, K., 71 Ramis, C., 275 Strecker, R. E., 759 Yokoo, H., 419 Mundy, W. R., 309 Ramos, J. A., 291 Strupczewski, J. T., 9 York, D. A., 487 Murakami, F., 945 Ranaldi, R., 343 Sufka, K. J., 507 Yoshida, M., 419 Muramatsu, I., 623 Rapoza, D., 179 Suzuki, T., 703, 881 Yoshii, T., 703 Murphy, M. R., 677 Refinetti, R., 27 Svingos, A. L., 759 Yoshikawa, T., 691 Myers, R. D., 233, 741 Renner, K. J., 837 Swann, A. C., 247 Young, R., 229, 865 Myhrer, T., 519 Rettori, M. C., 897 Swerdlow, N. R., 629 Myslobodsky, M. S., 55 Reynolds, I. J., 77 Sze, P. Y., 991 Zangrossi, Jr., H., 931 Rial, R., 275 Zini, I., 607 Najim, R. A., 597 Ribes, G., 369 Takeda, N., 817 Zupan, G., 19 Nakamura, J., 173, 445 Ricceri, L., 283 Takita, M., 623